Format

Send to

Choose Destination
See comment in PubMed Commons below
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29.

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Author information

  • 1Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen 72076, Germany;
  • 2Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen 72076, Germany; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen 72076, Germany;
  • 3Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen 72076, Germany; Department of Hematology and Oncology, University of Tübingen, Tübingen 72076, Germany;
  • 4Department of Hematology and Oncology, University of Tübingen, Tübingen 72076, Germany;
  • 5Department of Hematology and Oncology, University of Tübingen, Tübingen 72076, Germany; Clinical Cooperation Unit Translational Immunology, DKFZ Partner Site Tübingen, German Cancer Consortium (DKTK), Tübingen 72076, Germany; and.
  • 6Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen 72076, Germany; DKFZ Partner Site Tübingen, German Cancer Consortium (DKTK), Tübingen 72076, Germany.
  • 7Department of Hematology and Oncology, University of Tübingen, Tübingen 72076, Germany; juliane.stickel@med.uni-tuebingen.de.

Abstract

The breakthrough development of clinically effective immune checkpoint inhibitors illustrates the potential of T-cell-based immunotherapy to effectively treat malignancies. A remaining challenge is to increase and guide the specificities of anticancer immune responses, e.g., by therapeutic vaccination or by adoptive T-cell transfer. By analyzing the landscape of naturally presented HLA class I and II ligands of primary chronic lymphocytic leukemia (CLL), we delineated a novel category of tumor-associated T-cell antigens based on their exclusive and frequent representation in the HLA ligandome of leukemic cells. These antigens were validated across different stages and mutational subtypes of CLL and found to be robustly represented in HLA ligandomes of patients undergoing standard chemo-/immunotherapy. We demonstrate specific immune recognition of these antigens exclusively in CLL patients, with the frequencies of representation in CLL ligandomes correlating with the frequencies of immune recognition by patient T cells. Moreover, retrospective survival analysis revealed survival benefits for patients displaying immune responses to these antigens. These results directly imply these nonmutant self-peptides as pathophysiologically relevant tumor antigens and encourages their implementation for cancer immunotherapy.

KEYWORDS:

HLA; cancer immunotherapy; chronic lymphocytic leukemia; therapeutic vaccination; tumor-associated antigens

PMID:
25548167
PMCID:
PMC4299203
DOI:
10.1073/pnas.1416389112
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center